Superselective arterial infusion and concomitant radiotherapy for nasal cavity and paranasal sinus cancer

Thirty-seven patients with nasal cavity or paranasal sinus cancer received superselective intra-arterial infusion therapy of cisplatin and conventional concomitant extrabeam radiotherapy (RADPLAT). Five-year progression free rate of primary lesion and overall survival were 84% and 73% for all patients, respectively. Acute toxic effects were considered acceptable, however, severe toxic events occurred in some cases, namely, eye problems, tearing, obstructive sinusitis, osteoradionecrosis, and so on. We considered these complications did not severe compared with those of surgery. RADPLAT is considered to be one of the treatments for nasal cavity and paranasal sinus cancer. (author)